WHANIN PHARM CO.,LTD
Financials
Valuation Metrics
WHANIN PHARM CO.,LTD's Market Cap is ₩2013B. At end of 2025 it was ₩2106B. Ranked #802 of 2,405 in KR market (top 33%), #444 of 778 on KOSPI (top 57%), #87 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 38%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 201.25B KRW | KR#802/2,405 Sec#87/231 |
| Revenue | 273.47B KRW | KR#876/2,405 Sec#43/231 |
| Net Income | 20.45B KRW | KR#695/2,405 Sec#47/231 |
| Total Assets | 478.89B KRW | KR#787/2,405 Sec#45/231 |
| Net Assets | 421.01B KRW | KR#578/2,405 Sec#34/231 |
| Employees | 653 | KR#384/2,405 Sec#33/231 |
| Value | ||
| P/E | 9.84x | KR#856/2,405 Sec#41/231 |
| P/B | 0.48x | KR#822/2,405 Sec#33/231 |
| PEG | 0.40x | KR#681/2,405 Sec#43/231 |
| P/S | 0.74x | KR#1,229/2,405 Sec#65/231 |
| EV/EBITDA | 6.26x | KR#363/2,405 Sec#12/231 |
| FCF Yield | 3.82% | KR#954/2,405 Sec#58/231 |
| Profitability | ||
| ROE | 4.86% | KR#1,115/2,405 Sec#78/231 |
| ROA | 4.27% | KR#819/2,405 Sec#64/231 |
| Op. Margin | 8.16% | KR#643/2,405 Sec#52/231 |
| Revenue Growth | 5.71% | KR#1,146/2,405 Sec#113/231 |
| Earnings Growth | 24.65% | KR#679/2,405 Sec#46/231 |
| Financial Health | ||
| Debt Ratio | 13.75% | KR#221/2,405 Sec#37/231 |
| Total Debt | 2.01B KRW | KR#1,891/2,405 Sec#185/231 |
| FCF | 7.69B KRW | KR#787/2,405 Sec#46/231 |
| Cash | 63.58B KRW | KR#644/2,405 Sec#34/231 |
| Current Ratio | 4.26x | KR#347/2,405 Sec#55/231 |
| Net Debt/EBITDA | -2.76x | KR#177/2,405 Sec#6/231 |
| Dividend | ||
| Div. Yield | 2.76% | KR#751/2,405 Sec#37/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -5.09% | KR#712/2,405 Sec#40/231 |
| 1M Return | 5.56% | KR#159/2,405 Sec#15/231 |
| From 52W High | -10.87% | KR#55/2,405 Sec#2/231 |
| 1Y MDD | -22.63% | KR#95/2,405 Sec#5/231 |
| Trading | ||
| Volume | 65,133 shares | KR#824/2,405 Sec#89/231 |
| Trading Value | 694.3M KRW | KR#687/2,405 Sec#72/231 |
| Foreign Own. | 12.77% | KR#384/2,405 Sec#27/231 |
| Per Share | ||
| EPS | 1,100 KRW | KR#689/2,405 Sec#45/231 |
| BPS | 22,635 KRW | KR#490/2,405 Sec#33/231 |
Company Info
Established in 1978 and listed on the securities market in 1996, Whanin Pharmaceutical is a pharmaceutical manufacturing and sales company specializing in psychoneurotic agents. Based on 2024 IMS DATA, it holds the leading market share in the domestic psychotherapeutic drug market. With a robust drug lineup and strong network, the company boasts significant sales strengths in the psychoneurotic field and is growing with the market due to increasing prescriptions driven by the rise in mental health-related medical institutions and patient visits.